pembrolizumab

Open Access
Evaluating the Reproductive Impact of Pembrolizumab in Mice: Ovarian Function and Hormonal Changes
BENGÜ MUTLU SÜTCÜOĞLU, OSMAN SÜTCÜOĞLU, BETÜL ÖĞÜT, ORHUN AKDOĞAN, ÇAĞNUR ELPEN KODAZ, CANAN YILMAZ, ÖZLEM ERDEM, ELVAN ANADOL and NURIYE ÖZDEMIR

In Vivo January 2026, 40 (1) 191-201; DOI: https://doi.org/10.21873/invivo.14184
Open Access
Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced Bladder Cancer Recurrence Following Radical Cystectomy
YOSHIHIKO TASAKI, TAKASHI NAGAI, TAKU NAIKI, YUSUKE NODA, RYOSEI OKAWA, MISATO TOMITA, YOSUKE SUGIYAMA, YOSHIHISA MIMURA, KUNIHIRO ODAGIRI, NANAMI ITO, YUJI HOTTA, NOBUHIKO SHIMIZU, TOSHIKI ETANI, SHUZO HAMAMOTO, ATSUSHI OKADA, YOKO FURUKAWA-HIBI and TAKAHIRO YASUI

In Vivo July 2025, 39 (4) 2196-2208; DOI: https://doi.org/10.21873/invivo.14015
Open Access
Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab
MARTIN SVATON, MAGDALENA KNETKI-WROBLEWSKA, SYLWIA TABOR, PETR DOMECKY, ONDREJ VENCLICEK, JANA KREJCI, MARIE DROSSLEROVA, MICHAL HRNCIARIK, DANIEL HRICISAK, ALZBETA BEJCKOVA, ONDREJ FISCHER, MARTINA VITKOVA and MACIEJ KRZAKOWSKI

In Vivo September 2024, 38 (5) 2434-2440; DOI: https://doi.org/10.21873/invivo.13712
Open Access
C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab
HIROTAKA NAGASAKA, SHOTARO YAMAMOTO, ATSUTO SUZUKI, KIMITSUGU USUI, HIDEYUKI TERAO, NOBORU NAKAIGAWA and TAKESHI KISHIDA

In Vivo July 2024, 38 (4) 1823-1828; DOI: https://doi.org/10.21873/invivo.13634
Open Access
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report
TAKAHIRO HIRAI, MINEHIKO INOMATA, SHUHEI MINATOYAMA, MOE HASHIZUME, NAOKI TAKATA, KANA HAYASHI, ZENTA SETO, KOTARO TOKUI, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI, TOSHIRO MIWA, RYUJI HAYASHI, SHINICHI TANAKA, AKIRA NOGUCHI and TSUTOMU SATO

In Vivo May 2024, 38 (3) 1509-1511; DOI: https://doi.org/10.21873/invivo.13599
Open Access
Association of Nutritional Indices With Adverse Effects and Time-to-Treatment-Failure in Triple Therapy for Lung Cancer
YASUHISA HASHINO, TAKUMU MATUSHITA, TAE HATSUYAMA, AZUSA WAKAMOTO, KEISUKE GOTO, TAKANOBU HOSHI, KUNINORI IWAYAMA, KOICHI OHTAKI, TAKAKI TODA and HIDEKI SATO

In Vivo March 2024, 38 (2) 864-872; DOI: https://doi.org/10.21873/invivo.13512
Open Access
Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma
MIOKO MATSUO, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, MASAHIKO TAURA, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, RINA JIROMARU, TAKAHIRO HONGO, TOMOMI MANAKO and TAKASHI NAKAGAWA

In Vivo September 2023, 37 (5) 2188-2196; DOI: https://doi.org/10.21873/invivo.13318
Open Access
Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
TOMOMI MANAKO, RYUJI YASUMATSU, TAKAFUMI NAKANO, MIOKO MATSUO, TORANOSHIN TAKEUCHI, MASAHIKO TAURA, AKIHIRO TAMAE, MORIYASU YAMAUCHI, MUNEYUKI MASUDA, KENICHI TAGUCHI and TAKASHI NAKAGAWA

In Vivo March 2023, 37 (2) 747-755; DOI: https://doi.org/10.21873/invivo.13137
Open Access
Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases
CHIKA NAGAHISA, JUNPEI IIZUKA, YUKI KOBARI, RYO MINODA, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, HISASHI OKUDA, HIDEKI ISHIDA, YOJI NAGASHIMA and TOSHIO TAKAGI

In Vivo March 2023, 37 (2) 912-915; DOI: https://doi.org/10.21873/invivo.13162
You have access
A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab
GAI YAMASHITA, ISAKU OKAMOTO, AKIRA SHIMIZU, KUNIHIKO TOKASHIKI, TAKURO OKADA, HIROKI SATO and KIYOAKI TSUKAHARA

In Vivo March 2022, 36 (2) 1047-1051; DOI: https://doi.org/10.21873/invivo.12801

Main menu

User menu

Search

pembrolizumab

Pages